Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.

[1]  Kiyoko Kato,et al.  Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin , 2016, International Journal of Clinical Oncology.

[2]  Kazuhiro Yoshida,et al.  Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan , 2015, International Journal of Clinical Oncology.

[3]  R. Oishi,et al.  1481PDAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING WITH A MODERATELY EMETOGENIC CHEMOTHERAPY: A MULTICENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY IN JAPANESE GYNECOLOGIC PATIENTS RECEIVING PACLITAXEL AND CARBOPLATIN. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  K. Chida,et al.  Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. , 2014, Lung Cancer.

[5]  K. Yamaguchi,et al.  Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer , 2014, Supportive Care in Cancer.

[6]  H. Rugo,et al.  A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  G. Morrow,et al.  Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) , 2013, Supportive Care in Cancer.

[8]  K. Rabe,et al.  Management of non-small-cell lung cancer: recent developments , 2013, The Lancet.

[9]  S. Morita,et al.  A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy , 2013, British Journal of Cancer.

[10]  A. Sasse,et al.  Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. , 2012, Journal of the National Cancer Institute.

[11]  P. Hesketh,et al.  Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting , 2012, Supportive Care in Cancer.

[12]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Y. Li,et al.  The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo , 2010, Journal of Pharmacology and Experimental Therapeutics.

[14]  M. Kris,et al.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Aapro,et al.  Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Hardwick,et al.  Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study , 2010, Supportive Care in Cancer.

[17]  Thomas J. Smith,et al.  American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Scott,et al.  Palonosetron , 2009, Drugs.

[19]  T. Weisberg,et al.  Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy , 2009, Supportive Care in Cancer.

[20]  C. Kitagawa,et al.  Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. , 2009, The Lancet. Oncology.

[21]  P. Hesketh.  Chemotherapy-induced nausea and vomiting. , 2008, The New England journal of medicine.

[22]  H. Schmoll,et al.  Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. , 2007, The oncologist.

[23]  Panagiotis Mavros,et al.  Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Hajdenberg,et al.  Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. , 2006, The journal of supportive oncology.

[25]  F. Roila,et al.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Labianca,et al.  Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  K. Horgan,et al.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.

[28]  I. Olver,et al.  Antiemetic study methodology: recommendations for future studies. , 1996, Oncology.

[29]  S. Kohno,et al.  Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy , 2014, Supportive Care in Cancer.